Glenmark Specialty Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLENMARK SPECIALTY, and when can generic versions of GLENMARK SPECIALTY drugs launch?
GLENMARK SPECIALTY has one approved drug.
There are fourteen US patents protecting GLENMARK SPECIALTY drugs.
There are eighty patent family members on GLENMARK SPECIALTY drugs in thirty-two countries and twelve supplementary protection certificates in eleven countries.
Summary for Glenmark Specialty
| International Patents: | 80 |
| US Patents: | 14 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Glenmark Specialty
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 9,370,483 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 10,517,880 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 9,078,923 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Glenmark Specialty Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 112870203 | ⤷ Try a Trial |
| Japan | 2016534142 | ⤷ Try a Trial |
| Japan | 6768733 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glenmark Specialty Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3043773 | 2021045 | Norway | ⤷ Try a Trial | PRODUCT NAME: MOMETASON ELLER ET SALT DERAV OG OLOPATADIN ELLER ET SALT DERAV; NAT. REG. NO/DATE: 20-13278 20210709; FIRST REG. NO/DATE: 140638 20210426 |
| 3043773 | 57/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: MOMETASON ODER EIN SALZ DAVON UND OLOPATADIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: 140638 20210426 |
| 3043773 | C202130060 | Spain | ⤷ Try a Trial | PRODUCT NAME: MOMETASONA O UNA SAL DE LA MISMA Y OLOPATADINA O UNA SAL DE LA MISMA; NATIONAL AUTHORISATION NUMBER: 86059-SE/H/2040/001/DC; DATE OF AUTHORISATION: 20210701; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 140638; DATE OF FIRST AUTHORISATION IN EEA: 20210419 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
